長江健康(002435.SZ)：辛伐他汀片、注射用頭孢曲松鈉、注射用阿奇黴素通過一致性評價
格隆匯6月1日丨長江健康(002435.SZ)公佈，公司於近日收到旗下全資二級子公司海南海靈化學制藥有限公司(“海靈藥業”)的通知，其產品辛伐他汀片、注射用頭孢曲松鈉、注射用阿奇黴素已通過仿製藥質量和療效一致性評價，相關信息已在國家藥品監督管理局網站批准公示。
辛伐他汀片為降血脂藥。適用於原發性高膽固醇血癥包括雜合子家族性高膽固醇血癥、高脂血症或混合性高脂血症、純合子家族性高膽固醇血癥、冠心病合並高膽固醇血癥、及患有雜合子家族性高膽固醇血癥的兒童患者。根據米內網數據顯示，2020年中國城市公立醫院、縣級公立醫院、城市社區中心及鄉鎮衞生院(“中國公立醫療機構”)終端辛伐他汀口服劑型銷售額達10.2億元，其中片劑8.82億元。
頭孢曲松鈉是第三代廣譜、長效頭孢菌素類抗感染藥物，較第一、二代頭孢菌素對革蘭氏陰性菌的作用更強；與其他第三代頭孢菌素相比，具有半衰期長、組織穿透力強、毒副作用小等優勢，臨牀上主要用於敏感致病菌所致的下呼吸道感染、尿路、膽道感染，以及腹腔感染、盆腔感染、皮膚軟組織感染、骨和關節感染、敗血症、腦膜炎等及手術期感染預防。由於頭孢曲松鈉具有抗菌活性強、對部分β內酰胺酶穩定、血藥濃度維持時間長、不良反應少等特點，在臨牀上獲得廣泛應用，已被《抗菌藥物臨牀應用指導原則(2015)》、《中國腹腔感染診治指南(2019)》、《兒童社區獲得性肺炎診療規範(2019)》、《成人社區獲得性肺炎基層合理用藥指南(2020)》等國內權威指南推薦，目前為2020版國家醫保甲類及2018版國家基藥目錄品種。根據米內網數據顯示，頭孢曲松注射劑2020年中國公立醫療機構市場整體規模約31.5億元，市場前景廣闊。
阿奇黴素是第二代大環內酯類抗生素，對敏感革蘭陽性菌、革蘭陰性菌、衣原體、支原體等引起呼吸、泌尿系統感染有很好的療效。適應症為本品適用於敏感病原菌所致的下列感染：社區獲得性肺炎--由肺炎衣原體、流感嗜血桿菌、嗜肺軍團菌、卡他莫拉菌、肺炎支原體、金黃色葡萄球菌或肺炎鏈球菌等病原菌所致，且起始治療需靜脈給藥的患者。盆腔炎性疾病--由沙眼衣原體、淋球菌或人型支原體所致，且起初治療需靜脈給藥的病人。根據米內網數據顯示，阿奇黴素注射劑2020年中國公立醫療機構市場整體規模約7.7億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
